Adherium appointed Paul Mastoridis as CEO, succeeding Rick Legleiter.
Mastoridis, a pharmaceutical industry veteran with over 25 years of experience, is recognised for pioneering digital solutions in asthma and chronic obstructive pulmonary disease management.
His previous role as global medical head of respiratory at Novartis involved work in AI technology for differentiating and diagnosing asthma from COPD.
As CEO, Mastoridis aims to enhance Adherium's market penetration strategy, focusing on the immediate impact in the US of the Hailie Smartinhaler system.